Chronic Kidney Disease | Dialysis | HLA antibody identification | Single Antigen Bead-based Multiplex Assay
Item
diagnosed with chronic kidney disease and in dialysis with identified antibodies against at least two hla antigens of which at least one is 3000 mfi or more as measured by sab assay on at least two occasions.
boolean
C1561643 (UMLS CUI [1])
C0011946 (UMLS CUI [2])
C3508207 (UMLS CUI [3])
C4331290 (UMLS CUI [4])
Malignant Neoplasms | Exception Basal cell carcinoma Treated | Exception Squamous cell carcinoma of skin Treated | Exception Carcinoma in situ of uterine cervix | Exception Prostate carcinoma Gleason score | Exception Prostate carcinoma Prostate specific antigen measurement
Item
prior malignancy within 2 years excluding adequately treated basal cell or squamous cell skin cancer, cervical carcinoma in situ and prostate cancer gleason <6 and prostate-specific antigen (psa) <10 ng/ml.
boolean
C0006826 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0007117 (UMLS CUI [2,2])
C1522326 (UMLS CUI [2,3])
C1705847 (UMLS CUI [3,1])
C0553723 (UMLS CUI [3,2])
C1522326 (UMLS CUI [3,3])
C1705847 (UMLS CUI [4,1])
C0851140 (UMLS CUI [4,2])
C1705847 (UMLS CUI [5,1])
C0600139 (UMLS CUI [5,2])
C3203027 (UMLS CUI [5,3])
C1705847 (UMLS CUI [6,1])
C0600139 (UMLS CUI [6,2])
C0201544 (UMLS CUI [6,3])
Hepatitis B surface antigen positive | Hepatitis C antibody positive | HIV Seropositivity
Item
any positive result on screening for serum hepatitis b surface antigen, hepatitis c antibody and human immunodeficiency virus (hiv
boolean
C0149709 (UMLS CUI [1])
C0281863 (UMLS CUI [2])
C0019699 (UMLS CUI [3])
Sign or Symptom Communicable Disease
Item
clinical signs of ongoing infectious disease.
boolean
C3540840 (UMLS CUI [1,1])
C0009450 (UMLS CUI [1,2])
Condition Severe Treatment required for | Condition Severe Requirement Monitoring | Heart failure New York Heart Association Classification | Coronary Disease Unstable | Chronic Obstructive Airway Disease Oxygen Dependence
Item
severe other conditions requiring treatment and close monitoring, e.g. cardiac failure > new york heart association (nyha) grade 3, unstable coronary disease or oxygen dependent chronic obstructive pulmonary disease (copd)
boolean
C0348080 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C0332121 (UMLS CUI [1,3])
C0348080 (UMLS CUI [2,1])
C0205082 (UMLS CUI [2,2])
C1514873 (UMLS CUI [2,3])
C0026429 (UMLS CUI [2,4])
C0018801 (UMLS CUI [3,1])
C1275491 (UMLS CUI [3,2])
C1956346 (UMLS CUI [4,1])
C0443343 (UMLS CUI [4,2])
C0024117 (UMLS CUI [5,1])
C0030054 (UMLS CUI [5,2])
C0439857 (UMLS CUI [5,3])
Disease Study Subject Participation Status At risk | Disease Influence Research results | Disease Influence Study Subject Participation Status
Item
history of any other clinically significant disease or disorder which, in the opinion of the investigator, may either put the patient at increased risk because of participation in the study, or influence the results or the patient's ability to participate in the study
boolean
C0012634 (UMLS CUI [1,1])
C2348568 (UMLS CUI [1,2])
C1444641 (UMLS CUI [1,3])
C0012634 (UMLS CUI [2,1])
C4054723 (UMLS CUI [2,2])
C0683954 (UMLS CUI [2,3])
C0012634 (UMLS CUI [3,1])
C4054723 (UMLS CUI [3,2])
C2348568 (UMLS CUI [3,3])
Hypogammaglobulinemia | Total Serum IgG Test
Item
hypogammaglobulinemia defined as any values of p-total igg less than 3 g/l
boolean
C0086438 (UMLS CUI [1])
C1254650 (UMLS CUI [2])
Severe allergy | Hypersensitivity | Hypersensitivity Pharmaceutical Preparations IdeS protein Similar | Streptokinase allergy | Hypersensitivity Staphylokinase
Item
history of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the investigator or history of hypersensitivity to drugs with a similar chemical structure or class to ides (e. g streptokinase and/or staphylokinase)
boolean
C2945656 (UMLS CUI [1])
C0020517 (UMLS CUI [2])
C0020517 (UMLS CUI [3,1])
C0013227 (UMLS CUI [3,2])
C1564954 (UMLS CUI [3,3])
C2348205 (UMLS CUI [3,4])
C0572009 (UMLS CUI [4])
C0020517 (UMLS CUI [5,1])
C0143595 (UMLS CUI [5,2])
Compound Investigational | Study Subject Participation Status | Investigational New Drugs
Item
has received another new chemical entity (defined as a compound which has not been approved for marketing) or has participated in any other clinical study that included drug treatment within 4 months of the first administration of investigational product in this study. patients consented and screened but not dosed in previous studies are not excluded
boolean
C1706082 (UMLS CUI [1,1])
C1517586 (UMLS CUI [1,2])
C2348568 (UMLS CUI [2])
C0013230 (UMLS CUI [3])